---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-018808"
form_type: "8-K"
ticker: "CLDI"
cik: "0001855485"
company_name: "Calidi Biotherapeutics, Inc."
filed_at: "2025-07-11T23:59:59+00:00"
generated_at: "2026-05-18T06:58:40.096818+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Calidi shareholders approve reverse stock split and 3M-share equity plan increase

## Summary
- Elected James Schoeneck (6.5M for) and George Peoples (6.6M for) as Class II directors.
- Ratified CBIZ CPAs P.C. as auditor for FY2025 (15.6M for, 1.3M against).
- Approved reverse stock split ratio of 1:2 to 1:19, with board discretion on exact ratio.
- Approved amendment to 2023 Equity Plan increasing authorized shares from 393,780 to 3,393,780.
- All four proposals passed; quorum of 53.26% of shares represented.

## SEC filing metadata
- accession: 0001641172-25-018808
- form_type: 8-K
- ticker: CLDI
- cik: 0001855485
- company_name: Calidi Biotherapeutics, Inc.
- filed_at: 2025-07-11T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1855485/000164117225018808/0001641172-25-018808-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1855485/000164117225018808/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-018808
- JSON: https://secwatch.observer/filing/0001641172-25-018808.json
- Plain text: https://secwatch.observer/filing/0001641172-25-018808.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.